LYELL IMMUNOPHARMA IN

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

07 نوفمبر 2022 08:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

02 نوفمبر 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

06 أكتوبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 أكتوبر 2022 08:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

28 سبتمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

12 سبتمبر 2022 03:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

30 أغسطس 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

04 أغسطس 2022 16:05:03 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

07 يونيو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

10 مايو 2022 16:05:02 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

04 مايو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

29 مارس 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

08 مارس 2022 16:45:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

31 يناير 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

24 يناير 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

04 يناير 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

16 ديسمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

15 ديسمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair

02 ديسمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

12 نوفمبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire